NCT03248843View on ClinicalTrials.gov

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

KN035

Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).

Trial Locations (2)

216-8511

St. Marianna University School of Medicine Hospital, Kawasaki

104-0045

National Cancer Center Hospital, Tokyo

All Listed Sponsors
lead

3D Medicines (Sichuan) Co., Ltd.

INDUSTRY

NCT03248843 - A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter